Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more
Prothena Corporation plc (PRTA) - Total Assets
Latest total assets as of September 2025: $352.63 Million USD
Based on the latest financial reports, Prothena Corporation plc (PRTA) holds total assets worth $352.63 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Prothena Corporation plc - Total Assets Trend (2010–2024)
This chart illustrates how Prothena Corporation plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Prothena Corporation plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Prothena Corporation plc's total assets of $352.63 Million consist of 88.7% current assets and 11.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prothena Corporation plc's current assets represent 88.7% of total assets in 2024, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 86.2% of total assets in 2024, up from 0.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Prothena Corporation plc Competitors by Total Assets
Key competitors of Prothena Corporation plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Prothena Corporation plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Prothena Corporation plc generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Prothena Corporation plc is currently not profitable relative to its asset base.
Prothena Corporation plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.61 | 11.52 | 11.58 |
| Quick Ratio | 6.61 | 11.52 | 11.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $288.54 Million | $ 488.56 Million | $ 273.44 Million |
Prothena Corporation plc - Advanced Valuation Insights
This section examines the relationship between Prothena Corporation plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.62 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | -21.4% |
| Total Assets | $547.11 Million |
| Market Capitalization | $390.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Prothena Corporation plc's assets below their book value (0.71 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Prothena Corporation plc's assets decreased by 21.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Prothena Corporation plc (2010–2024)
The table below shows the annual total assets of Prothena Corporation plc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $547.11 Million | -21.44% |
| 2023-12-31 | $696.38 Million | -8.13% |
| 2022-12-31 | $758.03 Million | +24.40% |
| 2021-12-31 | $609.37 Million | +83.01% |
| 2020-12-31 | $332.98 Million | -20.58% |
| 2019-12-31 | $419.27 Million | -15.94% |
| 2018-12-31 | $498.80 Million | +0.50% |
| 2017-12-31 | $496.33 Million | +7.90% |
| 2016-12-31 | $459.98 Million | +19.40% |
| 2015-12-31 | $385.24 Million | +26.67% |
| 2014-12-31 | $304.12 Million | +66.72% |
| 2013-12-31 | $182.41 Million | +41.09% |
| 2012-12-31 | $129.28 Million | +3473.33% |
| 2011-12-31 | $3.62 Million | +9.64% |
| 2010-12-31 | $3.30 Million | -- |